Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4446-4454

  Cole, Peter D ^a   Vijayanathan, Veena ^a   Ali, Nafeeza F ^a   Wagshul, Mark E ^a   Tanenbaum, Eric J ^a   Price, Jeremy ^a   Dalal, Vidhi ^a   Gulinello, Maria E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; HOMOCYSTEIC ACID; MEMANTINE; METHOTREXATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXCITOTOXICITY; HIPPOCAMPUS; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPATIAL MEMORY; TREATMENT OUTCOME;

ANIMALS; COGNITION; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, SPINAL; MALE; MEMANTINE; MEMORY DISORDERS; METHOTREXATE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84882967330     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1179     Document Type: Article

References (43)

1. Kadan-Lottick NS, Zeltzer LK, Liu Q, Yasui Y, Ellenberg L, Gioia G, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010;102: 881-93.
2. Krull KR, Jain N, Pan Z, Shine K, Srivastava DK, Stewart D, et al. Executive functions in aging adult survivors of childhood leukemia. J Clin Oncol 28:15s, 2010 (suppl; abstr 9011).
3. Buizer AI, de Sonneville LM, Veerman AJ, Buizer AI, de Sonneville LMJ, Veerman AJP. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer 2009;52:447-54.
4. Lofstad GE, Reinfjell T, Hestad K, Diseth TH, Lofstad GE, Reinfjell T, et al. Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatrica 2009;98:180-6.
5. Conklin HM, Krull KR, Reddick WE, Pei D, Cheng C, Pui CH. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 2012;104:1386-95.
6. Ashford J, Schoffstall C, Reddick WE, Leone C, Laningham FH, Glass JO, et al. Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer 2010;116: 4638-45.
7. Waber DP, Queally JT, Catania L, Robaey P, Romero I, Adams H, et al. Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer 2012;58:758-65.
8. Moyer KH, Willard VW, Gross AM, Netson KL, Ashford JM, Kahalley LS, et al. The impact of attention on social functioning in survivors of pediatric acute lymphoblastic leukemia and brain tumors. Pediatr Blood Cancer 2012;59:1290-5.
9. Hocking MC, Alderfer MA. Neuropsychological sequelae of childhood cancer. In:Kreitler S, Ben-Arush MW, Martin A, editors. Pediatric Psycho-oncology: Psychosocial Aspects and Clinical Interventions. West Sussex, UK: John Wiley & Sons, Ltd.; 2012.
10. Kunin-Batson A, Kadan-Lottick NS, Cao Q, Brouwers P, Neglia JP. Neurocognitive Functioning Contributes to Quality of Life (QOL) After Childhood Acute Lymphoblastic Leukemia [abstract #49]. In: Proceedings of 12th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer; 2012 June 8-9; Williamsburg, VA. St. Jude Children's Research Hospital and National Cancer Institute; 2012.
11. Peterson CC, Johnson CE, Ramirez LY, Huestis S, Pai ALH, Demaree HA, et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;51:99-104.
12. Butler RW, Copeland DR, Fairclough DL, Mulhern RK, Katz ER, Kazak AE, et al. A multicenter, randomized clinical trial of a cognitive remediation program for childhood survivors of a pediatric malignancy. J Consult Clin Psychol 2008;76:367-78.
13. Li Y, Vijayanathan V, Gulinello M, Cole PD. Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 2010;95:428-33.
14. Vijayanathan V, Ali N, Gulinello M, Cole PD. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res 2011;225: 491-7.
15. Folbergrova J, Druga R, Otahal J, Haugvicova R, Mares P, Kubova H. Seizures induced in immature rats by homocysteic acid and the associated brain damage are prevented by group II metabotropic glutamate receptor agonist (2R, 4R)-4-aminopyrrolidine-2, 4-dicarbox-ylate. Exp Neurol 2005;192:420-36.
16. Folbergrova J, Haugvicova R, Mares P. Behavioral and metabolic changes in immature rats during seizures induced by homocysteic acid: the protective effect of NMDA and non-NMDA receptor antagonists. Exp Neurol 2000;161:336-45.
17. Gortz P, Hoinkes A, Fleischer W, Otto F, Schwahn B, Wendel U, et al. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J Neurol Sci 2004;218:109-14.
18. Turski WA. Homocysteic acid: convulsant action of stereoisomers in mice. Brain Res 1989;479:371-3.
19. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999;38:735-67.
20. Prusky GT, Harker KT, Douglas RM, Whishaw IQ. Variation in visual acuity within pigmented, and between pigmented and albino rat strains. Behav Brain Res 2002;136:339-48.
21. Bauer MS. Intensity and precision of circadian wheel running in three outbred rat strains. Physiol Behav 1990;47:397-401.
22. Whishaw IQ, Gorny B, Foroud A, Kleim JA. Long-Evans and Sprague-Dawley rats have similar skilled reaching success and limb representations in motor cortex but different movements: some cautionary insights into the selection of rat strains for neurobiological motor research. Behav Brain Res 2003;145:221-32.
23. Tonkiss J, Shultz P, Galler JR. Long-evans and sprague-dawley rats differ in their spatial navigation performance during ontogeny and at maturity. Dev Psychobiol 1992;25:567-79.
24. Andrews J. Possible confounding influence of strain, age and gender on cognitive performance in rats. Cogn Brain Res 1996;3:251-67.
25. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lympho-blastic leukemia (1985-2000). Leukemia 2010;24:320-34.
26. Li Y, Vijayanathan V, Gulinello ME, Cole PD. Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol Biochem Behav 2010;94:454-63.
27. Ennaceur A, Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav Brain Res 1992;51:83-92.
28. Kessels RP, Rijken S, Joosten-Weyn Banningh LW, Van Schuylen-borgh-VAN Es N, Olde Rikkert MG. Categorical spatial memory in patients with mild cognitive impairment and Alzheimer dementia: positional versus object-location recall. J Int Neuropsychol Soc 2010; 16:200-4.
29. Winters BD, Saksida LM, Bussey TJ. Implications of animal object memory research for human amnesia. Neuropsychologia 2010;48: 2251-61.
30. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 1999;41:649-56.
31. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30: 672-9.
32. Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, van Dam FS, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008;186:168-75.
33. Seigers R, Schagen SB, Coppens CM, van der Most PJ, van Dam FS, Koolhaas JM, et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 2009; 201:279-84.
34. Yang M, Kim J-S, Kim J, Kim S-H, Kim J-C, Kim J, et al. Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro. Biochem Pharmacol 2011;82:72-80.
35. Tagliari B, Zamin LL, Salbego CG, Netto CA, WyseATS. Homocysteine increases neuronal damage in hippocampal slices receiving oxygen and glucose deprivation. Metab Brain Dis 2006;21:273-8.
36. Algaidi SA, Christie LA, Jenkinson AM, Whalley L, Riedel G, Platt B. Long-term homocysteine exposure induces alterations in spatial learning, hippocampal signalling and synaptic plasticity. Exp Neurol 2006; 197:8-21.
37. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166:591-2.
38. Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist 2007;13:272-93.
39. FDA approves memantine drug for treating AD. Am J Alzheimer's Dis Other Demen 2003;18:329-30.
40. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-9.
41. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 2007; 191:141-7.
42. Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, et al. A pilot evaluation of the safety, tolerability, pharmaco-kinetics, and effectiveness of memantine in pediatric patients with attention-deficit/ hyperactivity disorder combined type. J Child Ado-lesc Psychopharmacol 2007;17:19-33.
43. Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16: 517-24. Development